Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma

Research output: Contribution to journalArticle

Standard

Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma. / Burmakin, Mikhail; van Wieringen, Tijs; Olsson, Olof; Stuhr, Linda; Åhgren, Aive; Heldin, Carl-Henrik; Reed, Rolf K; Rubin, Kristofer; Hellberg, Carina.

In: Journal of Translational Medicine, Vol. 15, No. 1, 47, 23.02.2017.

Research output: Contribution to journalArticle

Harvard

Burmakin, M, van Wieringen, T, Olsson, O, Stuhr, L, Åhgren, A, Heldin, C-H, Reed, RK, Rubin, K & Hellberg, C 2017, 'Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma', Journal of Translational Medicine, vol. 15, no. 1, 47. https://doi.org/10.1186/s12967-017-1142-7

APA

Burmakin, M., van Wieringen, T., Olsson, O., Stuhr, L., Åhgren, A., Heldin, C-H., ... Hellberg, C. (2017). Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma. Journal of Translational Medicine, 15(1), [47]. https://doi.org/10.1186/s12967-017-1142-7

CBE

MLA

Vancouver

Author

Burmakin, Mikhail ; van Wieringen, Tijs ; Olsson, Olof ; Stuhr, Linda ; Åhgren, Aive ; Heldin, Carl-Henrik ; Reed, Rolf K ; Rubin, Kristofer ; Hellberg, Carina. / Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.

RIS

TY - JOUR

T1 - Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma

AU - Burmakin, Mikhail

AU - van Wieringen, Tijs

AU - Olsson, Olof

AU - Stuhr, Linda

AU - Åhgren, Aive

AU - Heldin, Carl-Henrik

AU - Reed, Rolf K

AU - Rubin, Kristofer

AU - Hellberg, Carina

PY - 2017/2/23

Y1 - 2017/2/23

N2 - Background: Imatinib causes increased turnover of stromal collagen, reduces collagen fibril diameter, enhances extracellular fluid turnover and lowers interstitial fluid pressure (IFP) in the human colonic carcinoma KAT-4/HT-29 (KAT-4) xenograft model. Methods: We compared the effects of imatinib on oxygen levels, vascular morphology and IFP in three experimental tumor models differing in their content of a collagenous extracellular matrix. Results: Neither the KAT4 and CT-26 colonic carcinoma models, nor B16BB melanoma expressed PDGF β-receptors in the malignant cells. KAT-4 tumors exhibited a well-developed ECM in contrast to the other two model systems. The collagen content was substantially higher in KAT-4 than in CT-26, while collagen was not detectable in B16BB tumors. The pO2 was on average 5.4, 13.9 and 19.3 mmHg in KAT-4, CT-26 and B16BB tumors, respectively. Treatment with imatinib resulted in similar pO2-levels in all three tumor models but only in KAT-4 tumors did the increase reach statistical significance. It is likely that after imatinib treatment the increase in pO2 in KAT-4 tumors is caused by increased blood flow due to reduced vascular resistance. This notion is supported by the significant reduction observed in IFP in KAT-4 tumors after imatinib treatment. Vessel area varied between 4.5 and 7% in the three tumor models and was not affected by imatinib treatment. Imatinib had no effect on the fraction of proliferating cells, whereas the fraction of apoptotic cells increased to a similar degree in all three tumor models. Conclusion: Our data suggest that the effects of imatinib on pO2-levels depend on a well-developed ECM and provide further support to the suggestion that imatinib acts by causing interstitial stroma cells to produce a less dense ECM, which would in turn allow for an increased blood flow. The potential of imatinib treatment to render solid tumors more accessible to conventional treatments would therefore depend on the degree of tumor desmoplasia.

AB - Background: Imatinib causes increased turnover of stromal collagen, reduces collagen fibril diameter, enhances extracellular fluid turnover and lowers interstitial fluid pressure (IFP) in the human colonic carcinoma KAT-4/HT-29 (KAT-4) xenograft model. Methods: We compared the effects of imatinib on oxygen levels, vascular morphology and IFP in three experimental tumor models differing in their content of a collagenous extracellular matrix. Results: Neither the KAT4 and CT-26 colonic carcinoma models, nor B16BB melanoma expressed PDGF β-receptors in the malignant cells. KAT-4 tumors exhibited a well-developed ECM in contrast to the other two model systems. The collagen content was substantially higher in KAT-4 than in CT-26, while collagen was not detectable in B16BB tumors. The pO2 was on average 5.4, 13.9 and 19.3 mmHg in KAT-4, CT-26 and B16BB tumors, respectively. Treatment with imatinib resulted in similar pO2-levels in all three tumor models but only in KAT-4 tumors did the increase reach statistical significance. It is likely that after imatinib treatment the increase in pO2 in KAT-4 tumors is caused by increased blood flow due to reduced vascular resistance. This notion is supported by the significant reduction observed in IFP in KAT-4 tumors after imatinib treatment. Vessel area varied between 4.5 and 7% in the three tumor models and was not affected by imatinib treatment. Imatinib had no effect on the fraction of proliferating cells, whereas the fraction of apoptotic cells increased to a similar degree in all three tumor models. Conclusion: Our data suggest that the effects of imatinib on pO2-levels depend on a well-developed ECM and provide further support to the suggestion that imatinib acts by causing interstitial stroma cells to produce a less dense ECM, which would in turn allow for an increased blood flow. The potential of imatinib treatment to render solid tumors more accessible to conventional treatments would therefore depend on the degree of tumor desmoplasia.

KW - Hypoxia

KW - Interstitial fluid pressure

KW - Receptor tyrosine kinase

KW - Tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=85013804351&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1142-7

DO - 10.1186/s12967-017-1142-7

M3 - Article

VL - 15

JO - Journal of Translational Medicine

T2 - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 47

ER -